Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.

Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, Henriquez NV, Ten Dijke P, Borovecki F, Markwalder R, Thalmann GN, Papapoulos SE, Pelger RC, Vukicevic S, Cecchini MG, Löwik CW, van der Pluijm G.

Am J Pathol. 2007 Sep;171(3):1047-57.

2.

Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.

Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G.

Cancer Res. 2007 Sep 15;67(18):8742-51.

3.

Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.

Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P.

Cancer Res. 2005 Jul 1;65(13):5769-77.

4.

Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.

Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, Pai SK, Liu W, Fukuda K, Chambers C, Wilber A, Watabe K.

J Exp Med. 2011 Dec 19;208(13):2641-55. doi: 10.1084/jem.20110840. Epub 2011 Nov 28. Erratum in: J Exp Med. 2012 Mar 12;209(3):639.

5.

Bone morphogenetic protein 7 induces mesenchymal-to-epithelial transition in melanoma cells, leading to inhibition of metastasis.

Na YR, Seok SH, Kim DJ, Han JH, Kim TH, Jung H, Lee BH, Park JH.

Cancer Sci. 2009 Nov;100(11):2218-25. doi: 10.1111/j.1349-7006.2009.01301.x. Epub 2009 Jul 30.

6.

Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer.

van der Horst G, van den Hoogen C, Buijs JT, Cheung H, Bloys H, Pelger RC, Lorenzon G, Heckmann B, Feyen J, Pujuguet P, Blanque R, Clément-Lacroix P, van der Pluijm G.

Neoplasia. 2011 Jun;13(6):516-25.

7.

Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.

Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR.

J Bone Miner Res. 2005 Dec;20(12):2189-99. Epub 2005 Aug 1.

8.

BMP7: a new bone metastases prevention?

Fournier PG, Guise TA.

Am J Pathol. 2007 Sep;171(3):739-43. Epub 2007 Aug 9. No abstract available.

9.

Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways.

Yang S, Lim M, Pham LK, Kendall SE, Reddi AH, Altieri DC, Roy-Burman P.

Cancer Res. 2006 Apr 15;66(8):4285-90.

10.

The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis.

van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Pelger RC, van der Pluijm G.

Clin Exp Metastasis. 2011 Oct;28(7):615-25. doi: 10.1007/s10585-011-9395-7. Epub 2011 Jun 7.

11.

p38MAPK acts in the BMP7-dependent stimulatory pathway during epithelial cell morphogenesis and is regulated by Smad1.

Hu MC, Wasserman D, Hartwig S, Rosenblum ND.

J Biol Chem. 2004 Mar 26;279(13):12051-9. Epub 2004 Jan 12.

12.

The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.

Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P.

Cancer Res. 2006 Feb 15;66(4):2202-9.

13.

Bone morphogenetic protein 7 inhibits tumor growth of human uveal melanoma in vivo.

Notting I, Buijs J, Mintardjo R, van der Horst G, Vukicevic S, Lowik C, Schalij-Delfos N, Keunen J, van der Pluijm G.

Invest Ophthalmol Vis Sci. 2007 Nov;48(11):4882-9.

PMID:
17962434
14.

The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation.

Buijs JT, van der Horst G, van den Hoogen C, Cheung H, de Rooij B, Kroon J, Petersen M, van Overveld PG, Pelger RC, van der Pluijm G.

Oncogene. 2012 Apr 26;31(17):2164-74. doi: 10.1038/onc.2011.400. Epub 2011 Sep 26.

PMID:
21996751
15.
16.

BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.

Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R.

Nat Med. 2003 Jul;9(7):964-8.

PMID:
12808448
17.

Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.

Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG.

Int J Oncol. 2007 Feb;30(2):521-9.

PMID:
17203235
18.

Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer.

Masuda H, Fukabori Y, Nakano K, Takezawa Y, CSuzuki T, Yamanaka H.

Prostate. 2003 Mar 1;54(4):268-74.

PMID:
12539225
19.

Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.

Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE, Chung LW.

Cell Res. 2008 Aug;18(8):858-70. doi: 10.1038/cr.2008.84.

PMID:
18645583
20.

Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.

Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR.

Bone. 2006 Feb;38(2):154-66. Epub 2005 Aug 26.

PMID:
16126463
Items per page

Supplemental Content

Write to the Help Desk